Sanofi (EPA: SAN, NASDAQ: SNY) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a new indication for Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adult patients with newly diagnosed multiple myeloma (NDMM). This marks the fourth treatment regimen approved for Sarclisa in Japan since its initial approval in August 2020.
Drug Profile
Sarclisa, a CD38 monoclonal antibody, targets a specific epitope on the CD38 receptor on multiple myeloma cells, inducing distinct antitumor activity. The drug is now registered in over 50 countries and regions, including the US, European Union, Japan, and China, for various indications.-Fineline Info & Tech
